Terminated PHASE3 INTERVENTIONAL 2-arm NCT02433158

Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

An Open-Label Extension Study to Evaluate the Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

Sponsor: GlycoMimetics Incorporated

Conditions Pain Crisis Sickle Cell Anemia Sickle Cell Disease Sickle Cell Disorders Vaso-occlusive Crisis

Interventions Rivipansel

Updated 37 times since 2017 Last updated: Feb 8, 2021 Started: Dec 16, 2015 Primary completion: Nov 15, 2019 Completion: Nov 15, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The B5201003 OLE study was terminated based on the failure of the 'parent B5201002 study to meet its efficacy endpoints. Termination was not due to safety.

Other terminated trials from GlycoMimetics Incorporated

See all terminations from GlycoMimetics Incorporated

Listed as NCT02433158, this PHASE3 trial focuses on Pain Crisis and Sickle Cell Anemia and remains terminated or withdrawn. Sponsored by GlycoMimetics Incorporated, it has been updated 37 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

37 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Apr 2022 — Jul 2024 [monthly]

Terminated PHASE3
Dec 2021 — Apr 2022 [monthly]

Terminated PHASE3

▶ Show 32 earlier versions

Mar 2021 — Dec 2021 [monthly]

Terminated PHASE3
Feb 2021 — Mar 2021 [monthly]

Terminated PHASE3
Jan 2021 — Feb 2021 [monthly]

Terminated PHASE3
Nov 2020 — Jan 2021 [monthly]

Terminated PHASE3
Jul 2020 — Nov 2020 [monthly]

Terminated PHASE3
Jun 2020 — Jul 2020 [monthly]

Terminated PHASE3
Mar 2020 — Jun 2020 [monthly]

Terminated PHASE3
Jan 2020 — Mar 2020 [monthly]

Terminated PHASE3

Status: Active Not Recruiting → Terminated
Nov 2019 — Jan 2020 [monthly]

Active Not Recruiting PHASE3
Oct 2019 — Nov 2019 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Aug 2019 — Oct 2019 [monthly]

Recruiting PHASE3
Jul 2019 — Aug 2019 [monthly]

Recruiting PHASE3
Jun 2019 — Jul 2019 [monthly]

Recruiting PHASE3
Apr 2019 — Jun 2019 [monthly]

Recruiting PHASE3
Mar 2019 — Apr 2019 [monthly]

Recruiting PHASE3
Feb 2019 — Mar 2019 [monthly]

Recruiting PHASE3
Nov 2018 — Feb 2019 [monthly]

Recruiting PHASE3
Oct 2018 — Nov 2018 [monthly]

Recruiting PHASE3
Sep 2018 — Oct 2018 [monthly]

Recruiting PHASE3
Aug 2018 — Sep 2018 [monthly]

Recruiting PHASE3
Jul 2018 — Aug 2018 [monthly]

Recruiting PHASE3
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE3
Mar 2018 — Jun 2018 [monthly]

Recruiting PHASE3
Feb 2018 — Mar 2018 [monthly]

Recruiting PHASE3
Dec 2017 — Feb 2018 [monthly]

Recruiting PHASE3
Oct 2017 — Dec 2017 [monthly]

Recruiting PHASE3
Aug 2017 — Oct 2017 [monthly]

Recruiting PHASE3
Jul 2017 — Aug 2017 [monthly]

Recruiting PHASE3
Jun 2017 — Jul 2017 [monthly]

Recruiting PHASE3
May 2017 — Jun 2017 [monthly]

Recruiting PHASE3
Feb 2017 — May 2017 [monthly]

Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlycoMimetics Incorporated

Data source: GlycoMimetics Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Baltimore, United States , Boston, United States , Brooklyn, United States , Charleston, United States , Chicago, United States , Cincinnati, United States , Columbus, United States , Detroit, United States , Durham, United States and 25 more locations